Spectranetics, FDA Discuss Laser Indication Approval After Panel Says No
This article was originally published in The Gray Sheet
Spectranetics plans to use a 50-patient Belgium study to shore up support for an indication covering its CVX-300 excimer laser catheter system for critical limb ischemia patients with lesions not crossable with a guidewire
You may also be interested in...
Spectranetics hopes FDA will accept a retrospective analysis of bypass surgery data as a control arm to support a critical limb ischemia indication for its CVX-300 excimer laser catheter system in lieu of further clinical studies
FDA should have discouraged Spectranetics from conducting a non-randomized trial for critical limb ischemia (CLI), Circulatory System Devices Panel members asserted Oct. 2
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.